Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid

Author:  ["Catherine Vilchèze","Feng Wang","Masayoshi Arai","Manzour Hernando Hazbón","Roberto Colangeli","Laurent Kremer","Torin R Weisbrod","David Alland","James C Sacchettini","William R Jacobs Jr"]

Publication:  Nature Medicine

CITE.CC academic search helps you expand the influence of your papers.

Tags:     Medicine

Abstract

Isoniazid is one of the most effective antituberculosis drugs, yet its precise mechanism of action is still controversial. Using specialized linkage transduction, a single point mutation allele (S94A) within the putative target gene inhA was transferred in Mycobacterium tuberculosis. The inhA(S94A) allele was sufficient to confer clinically relevant levels of resistance to isoniazid killing and inhibition of mycolic acid biosynthesis. This resistance correlated with the decreased binding of the INH-NAD inhibitor to InhA, as shown by enzymatic and X-ray crystallographic analyses, and establishes InhA as the primary target of isoniazid action in M. tuberculosis.

Cite this article

Vilchèze, C., Wang, F., Arai, M. et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med 12, 1027–1029 (2006). https://doi.org/10.1038/nm1466

View full text

>> Full Text:   Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid

Role of deficient type III interferon-λ production in asthma exacerbations

NR4A orphan nuclear receptors are transcriptional regulators of hepatic glucose metabolism